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 Atrial fi brillation is far more common in 
patients with end-stage renal disease 
(ESRD) than in the general population. 
However, estimates of its prevalence vary 
widely in the literature. Th is Commentary 
addresses the relevance of methods of 
defining atrial fibrillation in ESRD 
patients, and the numerous unaddressed 
questions on how to treat atrial fi brillation 
in this population. 
 Th e prevalence of atrial fi brillation in 
the general public rises with age from 
0.4 – 1.0 % overall to approximately 8 % in 
people in their ninth decade of life. 1 Prior 
estimates of the prevalence of atrial fi bril-
lation among end-stage renal disease 
(ESRD) patients, however, dwarf the fre-
quency in the general population, but they 
have varied widely, ranging from 10.9 to 
27 % depending on the population stud-
ied. 2 – 5 Further, mortality among people 
with ESRD and atrial fibrillation is 
increased almost twofold from the already 
high rates for those with ESRD but with-
out atrial fibrillation. 5 Given the more 
than 1.5 million people with ESRD inter-
nationally, a thorough understanding 
of the burden of atrial fibrillation in 
our patients with ESRD is essential for 
understanding the magnitude of the gaps 
in evidence-based treatment. 6 
 Wetmore  et al. 7 (this issue) present an 
estimate of the prevalence of atrial fi brilla-
tion in a novel database of US patients eli-
gible for both Medicare and Medicaid. 
Using billing claims, they identified 
patients with atrial fi brillation and esti-
mated its prevalence at 7.0 % , with a tight 
range (95 % confi dence interval 6.8 – 7.2 % ) 
given the size of the data set (  >  63,000 peo-
ple). Th e strength of this estimate is based 
on the rigorous way in which people with 
atrial fi brillation were identifi ed, focusing 
on its clinical relevance. For a patient to be 
categorized as having atrial fi brillation, the 
diagnosis had to appear in at least two bill-
ing claims separated by more than 30 days, 
at least one of which had to be outpatient. 
Th is estimate of prevalence, although lower 
than the previously reported range, should 
not discount the burden of disease, as we 
can now state that atrial fi brillation is as 
common overall in the entire population 
of people with ESRD as it is in the group 
with the highest burden (those in their 
80  s) in the general population. 
 In light of this tremendous burden of 
disease, what do we know about its treat-
ment in people with ESRD ( Figure 1 )? We 
know that the risk – benefi t ratio of antico-
agulation in patients with ESRD and atrial 
fi brillation is not the same as that among 
those with normal kidney function. No 
randomized trials have been done. How-
ever, an observational cohort study of more 
than 48,000 ESRD patients examined the 
1671 patients with documented atrial fi bril-
lation. 8 Of those, 508 received warfarin, 43 
received clopidogrel, 304 received aspirin, 
336 received two or more of these treat-
ments, and 480 received no anticoagulation 
or antiplatelet treatment for the prevention 
of stroke. Because this was an observational 
study, comparison of outcomes among 
groups is limited by the indication bias 
associated with the therapy chosen. Patients 
receiving warfarin were more likely to be 
male and less likely to have comorbidities 
such as diabetes, coronary artery disease, 
and prior history of stroke. However, with 
those biases in mind, the highest rate of 
new strokes was seen among those receiv-
ing warfarin (7.1 per 100 person-years at 
risk), followed by those receiving aspirin, 
no treatment, and clopidogrel (3.5, 2.9, and 
2.7 per 100 person-years at risk, respec-
tively). Although observational data can 
establish only association, not cause and 
eff ect, these data strongly support the con-
clusion that warfarin may not be the best 
treatment for people with ESRD and atrial 
fi brillation. Given the small numbers of 
patients receiving antiplatelet therapy, it is 
not possible to address whether these 
agents provide a reduction in stroke risk. 
 New therapeutic options for the preven-
tion of stroke in atrial fi brillation include 
the oral factor Xa inhibitors apixaban and 
rivaroxaban. 9,10 Both demonstrated non-
inferiority when compared with warfarin, 
with trends toward superiority, but neither 
study enrolled sufficient numbers of 
patients with severe kidney disease or 
ESRD to examine their effi  cacy in these 
populations. Given that both agents saw a 
decrement in the rate of hemorrhagic 
stroke and bleeding episodes as compared 
with the control arm receiving warfarin, 
the potential exists for a therapeutic ben-
efi t among those with ESRD. However, in 
that these drugs are partially cleared by 
the kidneys, dedicated trials are of para-
mount importance. 
 From the studies published in the tradi-
tionally renal literature, one would con-
clude that the only relevant clinical 
questions for patients with ESRD are preva-
lence and the choice as to whether or not 
to anticoagulate. However, a plethora of 
even more essential questions remain to be 
addressed among people with atrial fi bril-
lation and kidney disease. 
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 Th e newly updated guidelines on the 
treatment of atrial fi brillation 11 highlight 
the results of two recently published trials 
assessing how to approach rate control. 
Th e RACE II (Rate Control Effi  cacy in Per-
manent Atrial Fibrillation) trial rand-
omized patients with atrial fi brillation to 
strict control (resting heart rate   <  80 beats 
per minute) vs. lenient control (resting 
heart rate   <  110 beats per minute) and 
observed the effect on cardiovascular 
death, heart failure hospitalization, stroke, 
systemic embolism, bleeding, and life-
threatening arrhythmias. 12 Over the 3-year 
follow up, one of these cardiovascular 
events was seen in 12.9 % of the lenient-
control group and 14.9 % of the strict-
control group. Additionally, the Atrial 
Fibrillation and Congestive Heart Failure 
Trial was completed, randomizing subjects 
to rhythm control using amiodarone and 
cardioversion as compared with rate con-
trol using beta-blockers and digitalis. 13 No 
diff erences were seen between groups with 
respect to death, heart failure, or stroke, 
but the group randomized to rhythm con-
trol was more likely to require hospitaliza-
tion during the course of the trial. 
 Th e ability to extrapolate these some-
what counterintuitive results to patients 
with kidney disease is again, however, lim-
ited. Th e diff erences in blood vessel com-
pliance as measured by pulse pressure 13 
and the complexity of the associations 
between hemodynamic changes on dialy-
sis and mortality 14 in comparison with 
people with normal kidney function 
may modify the eff ect of whether rhythm 
control is achieved and of to what extent 
rate control is maintained. Given that an 
estimated 20 % of ventricular fi lling occurs 
due to the  ‘ atrial kick ’ and that cardiac out-
put is directly related to stroke volume, the 
question of how important adequate ven-
tricular fi lling is during times of cardio-
vascular stress such as hemodialysis with 
4  l of ultrafi ltration may have a diff erent 
answer in someone with ESRD. 
 Finally, future directions in the 
treatment of atrial fibrillation include 
catheter-based oblation for symptomatic 
paroxysmal atrial fibrillation that has 
failed one or more drugs. In the Th ermo-
Cool trial, recurrence of symptomatic 
atrial fi brillation occurred in 34 % of the 
group receiving oblation during the 
9 months of follow-up as compared with 
84 % of those receiving medications for 
rate of rhythm control. 15 There are no 
data for patients with ESRD. But given the 
real lack of data on safety for any of the 
agents recommended for use in rate and 
rhythm control (amiodarone, dofetilide, 
dronedarone, propafenone, sotalol, and 
fl ecainide) and the risk associated with 
anticoagulation, perhaps this will be the 
most therapeutic option. 
 Whether we are estimating that 7 % of 
500,000 or 7 % of 1.5 million have atrial 
fi brillation in the United States or world-
wide, the paucity of data on treatment 
is remarkable. Given the huge burden 
demonstrated with the conservative and 
specifi c criteria used by Wetmore  et al. , 7 
there is defi nitely justifi cation (if there 
was not before) to conduct trials to truly 
understand and treat this dangerous 
comorbidity. 
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To-do list for research on atrial fibrillation in people with ESRD
Define burden of disease and impact on outcomes
Determine best anticoagulation strategy
Define whether rate or rhythm control maximizes outcomes
Describe safety of antiarrhythmics in people with ESRD
Explore catheter oblation as a viable alternative to medical therapy
 Figure 1  |  To-do list for research on atrial fibrillation in people with ESRD. ESRD, end-stage 
renal disease. 
